VestGen Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 37,263 shares of the company’s stock, valued at approximately $3,746,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IHE. Balance Wealth Partners LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth $42,000. Root Financial Partners LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the third quarter valued at approximately $51,000. Trust Co. of Vermont acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at approximately $60,000. Turtle Creek Wealth Advisors LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the third quarter valued at $64,000. Finally, Mather Group LLC. acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at approximately $75,000.
iShares U.S. Pharmaceuticals ETF Price Performance
IHE stock opened at $106.61 on Friday. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47. The company has a 50 day simple moving average of $102.38 and a 200 day simple moving average of $94.63. iShares U.S. Pharmaceuticals ETF has a 1 year low of $74.38 and a 1 year high of $108.66.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Read More
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
